WFRF:(Wennborg Anders)
Sökning: WFRF:(Wennborg Anders) > Development and pre...
Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake
-
- Ekblad, Torun (författare)
- KTH,Skolan för bioteknologi (BIO)
-
- Tran, Thuy (författare)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University
-
- Orlova, Anna (författare)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University
- visa fler...
- visa färre...
- (creator_code:org_t)
- 2008-07-02
- 2008
- Engelska.
- Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer Science and Business Media LLC. - 1619-7070 .- 1619-7089. ; 35:12, s. 2245-2255
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- Purpose Affibody molecules are low molecular weight proteins (7 kDa), which can be selected to bind to tumour-associated target proteins with subnanomolar affinity. Because of rapid tumour localisation and clearance from nonspecific compartments, Affibody molecules are promising tracers for molecular imaging. Earlier, 99mTc-labelled Affibody molecules demonstrated specific targeting of tumour xenografts. However, the biodistribution was suboptimal either because of hepatobiliary excretion or high renal uptake of the radioactivity. The goal of this study was to optimise the biodistribution of Affibody molecules by chelator engineering. Materials and methods Anti-HER2 ZHER2:342 Affibody molecules, carrying the mercaptoacetyl-glutamyl-seryl-glutamyl (maESE), mercaptoacetyl-glutamyl-glutamyl-seryl (maEES) and mercaptoacetyl-seryl-glutamyl-glutamyl (maSEE) chelators, were prepared by peptide synthesis and labelled with 99mTc. The tumour-targeting capacity of these conjugates was compared with each other and with the best previously available conjugate, 99mTc-maEEE-ZHER2:342, in nude mice bearing SKOV-3 xenografts. The tumour-targeting capacity of the most promising conjugate, 99mTc-maESE-ZHER2:342, was compared with radioiodinated ZHER2:342. Results All novel conjugates demonstrated successful tumour targeting and a low degree of hepatobiliary excretion. The renal uptakes of serine-containing conjugates, 33 ± 5, 68 ± 21 and 71 ± 10%IA/g, for99mTc-maESE-ZHER2:342, 99mTc-maEES-ZHER2:342 and 99mTc-maSEE-ZHER2:342, respectively, were significantly reduced in comparison with 99mTc-maEEE-ZHER2:342 (102 ± 13%IA/g). For 99mTc-maESE-ZHER2:342, a tumour uptake of 9.6 ± 1.8%IA/g and a tumour-to-blood ratio of 58 ± 6 were reached at 4 h p.i. Conclusions A combination of serine and glutamic acid residues in the chelator sequence confers increased renal excretion and relatively low renal uptake of 99mTc-labelled Affibody molecules. In combination with preserved targeting capacity, this improved imaging of targets in abdominal area.
Nyckelord
- Affibody molecule
- HER2
- Renal uptake
- Technetium-99m
- Tumour targeting
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
- European Journal of Nuclear Medicine and Molecular Imaging (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
Hitta mer i SwePub
- Av författaren/redakt...
- Ekblad, Torun
- Tran, Thuy
- Orlova, Anna
- Widström, Charle ...
- Feldwisch, Joach ...
- Abrahmsén, Lars
- visa fler...
- Wennborg, Anders
- Eriksson Karlstr ...
- Tolmachev, Vladi ...
- visa färre...
- Artiklar i publikationen
- European Journal ...
- Av lärosätet
- Uppsala universitet
- Kungliga Tekniska Högskolan
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
